Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.55 |
| ▸ | PNMT | P11086 | 7/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1919026 | 1.00 | GRIN2B (0.55) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL3442261 | 0.90 | DRD2 (0.54) | GRIN2BPNMTADRA2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL8187018 | 0.89 | DRD2 (0.53) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL9483063 | 0.83 | PNMT (0.65) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL30709850 | 0.83 | PNMT (0.65) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL2832699 | 0.82 | GRIN2B (0.54) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL24773358 | 0.80 | GRIN2B (0.52) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL1715396 | 0.80 | PNMT (0.61) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL2083495 | 0.80 | PNMT (0.61) | GRIN2BPNMTADRA2AMEN1LMNA | |
| SCHEMBL12670596 | 0.79 | GRIN2B (0.61) | GRIN2BPNMTADRA2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010083465-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | WO | disclosed |